Abstract:Objective To investigate the expression and clinical significance of soluble scavenger receptor CD163 in serum of patients with chronic obstructive pulmonary disease (COPD). Methods Totally 100 patients with chronic obstructive pulmonary disease, including 45 patients with acute exacerbation and 55 patients with stable disease, in addition, 50 cases of healthy people as control group. The changes of serum soluble scavenger receptor CD163 in the acute exacerbation group, stable phase group and control group were compared. Three groups of lung function related indicators were measured, and the correlation between serum soluble scavenger receptor CD163 and lung function was analyzed. The clinical value of serum soluble scavenger receptor CD163 in the diagnosis of chronic obstructive pulmonary disease was analyzed by ROC curve. Results The differences of serum soluble scavenger receptor CD163 levels in the three groups were statistically significant (P?0.05). Compared with the control group, the levels of receptor CD163 in the acute exacerbation group and the stable phase group were increased (P?0.05). Compared with the stable group, the serum soluble scavenger receptor CD163 level was increased in the acute exacerbation group (P?0.05). The differences between the three groups of FEV1, PEF, FEV1% and FEV1%pred were statistically significant (P?0.05). Compared with the control group, the FEV1, PEF, FEV1% and FEV1%pred measurements were decreased in the acute exacerbation group and the stable phase group (P?< 0.05). Compared with the stable phase group, the patients in the acute exacerbation group were FEV1, PEF, and FEV1% and FEV1%pred measurements were reduced (P?0.05). Sperman correlation analysis showed that serum CD163 levels were negatively correlated with FEV1% and FEV1%pred in patients with acute exacerbation (rs?=?-0.833 and -0.805, all P?= 0.000); the serum CD163 levels in stable patients FEV1% and FEV1%pred were negatively correlated (rs?=?-0.714 and -0.643, all P?=?0.000); the area under the curve of serum CD163 for the diagnosis of acute exacerbation of chronic obstructive pulmonary disease was 0.821 (95% CI: 0.629, 0.976), diagnostic sensitivity was 0.928, specificity was 0.803; the area under the curve for the diagnosis of chronic obstructive pulmonary disease was 0.784 (95% CI: 0.436, 0.761), diagnostic sensitivity was 0.872, specificity was 0.741. Conclusions The soluble scavenger receptor CD163 is highly expressed in the serum of patients with chronic obstructive pulmonary disease, and it’s expression is closely related to the lung function of patients. Perhaps, it will become a clinical test for chronic obstructive pulmonary disease.